CompletedNCT00142961
Atomoxetine for adolescents with ADHD who use marijuana
About this title
Read the official source — NCT00142961Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in people with ADHD.
Medication studyAges 14–21United States
Understand this study
What did researchers investigate?
Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in people with ADHD.
Who was this study for?
Listed age limits: 14 years to 21 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateOctober 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 2
- Sponsor
- New York State Psychiatric Institute
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 14 Years to 21 Years
- Official registry ID
- NCT00142961
- Official title
Show the full official title
Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared atomoxetine and placebo to find out how the approaches affected ADHD symptoms in people with ADHD.
Who is behind this study?
The study sponsor is New York State Psychiatric Institute, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
Listed age limits: 14 years to 21 years.
